JAC Advance Access published online on October 4, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki353
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Section of Microbiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
* To whom correspondence should be addressed. Objectives: Fluoroquinolones are being used more frequently for the treatment of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis complex (MTB). This study was designed to determine the frequency of the emergence of fluoroquinolone-resistant strains in Taiwan and to assess whether this might be due to use of fluoroquinolones for treatment of patients with MDR or because of increased use of fluoroquinolones in the community for treatment of other infections. We also sought to determine whether there might be clonal spread of fluoroquinolone resistance. Methods: A total of 3497 clinical isolates of M. tuberculosis complex were obtained during 1995-2003, of which 141 were selected. They consisted of 62 isolates fully susceptible to four first-line drugs, 33 isolates resistant to rifampicin and isoniazid (MDR), and 46 isolates with a variety of any drug resistant patterns other than MDR (combination group). The MICs were determined for ciprofloxacin, ofloxacin and levofloxacin. Results: An increase in the MIC90 and rates of resistance to ciprofloxacin, ofloxacin and levofloxacin were noted only in the MDR group. The rates were higher among strains isolated between 1998-2003 compared with those obtained between 1995-1997 (rate of resistance, 20% versus 7.7%; MIC Conclusions: These findings suggest that fluoroquinolone resistance is the result of treatment of patients with MDR strains rather than from use in the general community in Taiwan. The emergence of fluoroquinolone resistance among MDR strains reinforces the need for routine fluoroquinolone susceptibility testing whenever these drugs might be used.
Received May 3, 2005
Revised August 14, 2005
Accepted September 8, 2005
Original article
Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003
2 Department of Internal Medicine, Ohio State University, Columbus, OH, USA
3 Section of Infectious Diseases, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; National Yang-Ming University, Taipei, Taiwan
4 Section of Infectious Diseases, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
Yung-Ching Liu, E-mail: ycliu{at}isca.vghks.gov.tw
Abstract 
4 mg/L versus 1-2 mg/L). Among the 10 fluoroquinolone-resistant isolates, five (50%) possessed mutations other than S95T in the gyrA gene. No gyrB mutation was found in any of the clinical isolates.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Bernardo and W. W. Yew How Are We Creating Fluoroquinolone-resistant Tuberculosis? Am. J. Respir. Crit. Care Med., August 15, 2009; 180(4): 288 - 289. [Full Text] [PDF]
|
|
|
|
 |
|
 J. van den Boogaard, G. S. Kibiki, E. R. Kisanga, M. J. Boeree, and R. E. Aarnoutse New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development Antimicrob. Agents Chemother., March 1, 2009; 53(3): 849 - 862. [Full Text] [PDF]
|
|
|
|
|
|
I. Mokrousov, T. Otten, O. Manicheva, Y. Potapova, B. Vishnevsky, O. Narvskaya, and N. Rastogi Molecular Characterization of Ofloxacin-Resistant Mycobacterium tuberculosis Strains from Russia Antimicrob. Agents Chemother., August 1, 2008; 52(8): 2937 - 2939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-S. Huang, Y.-C. Liu, C.-L. Sy, Y.-S. Chen, H.-Z. Tu, and B.-C. Chen In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis Complex Isolated in Taiwan over 10 Years Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2226 - 2227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Wang, L.-N. Lee, H.-C. Lai, S.-K. Wang, I-S. Jan, C.-J. Yu, P.-R. Hsueh, and P.-C. Yang Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure J. Antimicrob. Chemother., May 1, 2007; 59(5): 860 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Nahid, M. Pai, and P. C. Hopewell Advances in the diagnosis and treatment of tuberculosis. Proceedings of the ATS, January 1, 2006; 3(1): 103 - 110. [Abstract] [Full Text] [PDF]
|
|